Regeneron Pharmaceuticals, Inc.REGN
What Regeneron Pharmaceuticals, Inc. does.
This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others:
• competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates");
• uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties or other factors beyond Regeneron's control on the commercial success of Regeneron's Products and Regeneron's Product Candidates;
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.5B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| Net income | $3.5B | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B |
| Free cash flow | $2.0B | $6.5B | $4.4B | $3.9B | $3.7B | $4.1B |
More on REGN.
- Regeneron Pharmaceuticals, Inc. summary
- Regeneron Pharmaceuticals, Inc. financial statements
- Regeneron Pharmaceuticals, Inc. key metrics
- Regeneron Pharmaceuticals, Inc. health scores and style box
- Regeneron Pharmaceuticals, Inc. earnings
- Regeneron Pharmaceuticals, Inc. dividends
- Regeneron Pharmaceuticals, Inc. valuation
- Regeneron Pharmaceuticals, Inc. ownership and insiders
- Regeneron Pharmaceuticals, Inc. peers
Figures from Regeneron Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.